Results 21 to 30 of about 352,135 (348)
Blood Cancer Journal, 2021 Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality.
Paola Guglielmelli +15 more
doaj +1 more source
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
Research and Practice in Thrombosis and Haemostasis, 2022 A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was presented at the ISTH congress in 2021. We summarize here the main points of the lecture with two purposes: to report the incidence rates of major thrombosis in ...
T. Barbui, A. Carobbio, V. De Stefano
semanticscholar +1 more source
Myeloproliferative neoplasms [PDF]
Clinical Medicine, 2013 The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy ...
Amy, Publicover, Patrick, Medd
openaire +2 more sources
Renal disease associated with chronic myeloproliferative neoplasms
Expert Review of Hematology, 2022 Patients with BCR-ABL negative chronic myeloproliferative neoplasms (MPNs) present with chronic kidney disease (CKD) in up to one third of cases. These patients are known to have increased cardiovascular risk and usually present with features of stronger
M. Lucijanić, I. Krečak, R. Kušec
semanticscholar +1 more source
Deactylase inhibition in myeloproliferative neoplasms [PDF]
Investigational New Drugs, 2010 Myeloproliferative neoplasms (MPN) are clonal haemopoietic progenitor cell disorders characterized by the proliferation of one or more of the haemopoietic lineages (myeloid, erythroid and/or megakaryocytic). The MPNs include eight haematological disorders: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET ...
Sridurga Mithraprabhu +3 more
openalex +5 more sources
Biomolecules, 2022 The JAK2V617F variant constitutes a genetic alteration of higher frequency in BCR/ABL1 negative chronic myeloproliferative neoplasms, which is caused by a substitution of a G ˃ T at position 1849 and results in the substitution of valine with ...
Dania G. Torres +6 more
semanticscholar +1 more source
Pathogenesis of myeloproliferative neoplasms [PDF]
Experimental Hematology, 2015 Major progress has been recently made in understanding the molecular pathogenesis of myeloproliferative neoplasms (MPN). Mutations in one of four genes-JAK2, MPL, CALR, and CSF3R-can be found in the vast majority of patients with MPN and represent driver mutations that can induce the MPN phenotype.
Skoda, Radek C. +2 more
openaire +3 more sources
Genetics of Myeloproliferative Neoplasms
Hematology/Oncology Clinics of North America, 2021 Myeloproliferative neoplasms are hematopoietic stem cell disorders based on somatic mutations in JAK2, calreticulin, or MPL activating JAK-STAT signaling. Modern sequencing efforts have revealed the genomic landscape of myeloproliferative neoplasms with additional genetic alterations mainly in epigenetic modifiers and splicing factors.
Szybinski, Jakub, Meyer, Sara C.
openaire +4 more sources
Haematologica, 2022 Apart from the central role of the activated JAK/STAT signaling pathway, ASXL1 mutations are the most recurrent additional mutations in myeloproliferative neoplasms and occur much more commonly in myelofibrosis than in essential thrombocythemia and ...
Zhongxun Shi +19 more
semanticscholar +1 more source
European Heart Journal, 2021 Inflammation contributes centrally to cardiovascular diseases, and anti-inflammatory treatments can reduce cardiovascular events. The JAK-STAT pathway is an emerging target in inflammation, mainly in rheumatoid arthritis (RA) and chronic ...
C. Baldini +4 more
semanticscholar +1 more source